To the Editor: In their study of guest authorship and ghostwriting of publications related to rofecoxib, Dr Ross and colleagues1 selected an article by Thal et al2 as their primary example of an apparently guest-authored clinical trial publication. Guest authorship was inferred because (1) an early draft identified as part of rofecoxib litigation indicated “External author?” rather than the first 3 names later included; (2) only 1 of these 3 academically affiliated authors was acknowledged in the draft version as a participating investigator in the Rofecoxib 078 study group; and (3) results in the 2 versions were quite similar. The article and accompanying Editorial by Drs DeAngelis and Fontanarosa3 assumed that these authors had little or no role in either the study or in preparing the publication and therefore were uninvolved “guest” authors.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.